Special drug-use survey of Tarlige (central neuropathic pain)

JRCT ID: jRCT2031220132

Registered date:12/06/2022

Basic Information

• Recruitment status: Not Recruiting
• Health condition(s) or Problem(s) studied: Central neuropathic pain
• Date of first enrollment: 04/07/2022
• Target sample size: 400
• Study type: Observational

Outcome(s)

• Primary Outcome: Occurrence of adverse drug reactions stratified by the causative diseases of neuropathic pain
• Secondary Outcome: Change in VAS (Visual Analogue Scale) of pain

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Both

Include criteria

(1) Patients with central neuropathic pain not treated with Tarlige before
(2) Patients who started administration of Tarlige during the contract period (contract period based on the contract with each medical site)
(3) Patients who started administration of Tarlige during the registration period
(4) Patients from whom written informed consent was obtained

• Exclude criteria: none

Related Information

• Primary Sponsor: Tanabe Hirokazu